JP2024054286A5 - - Google Patents

Download PDF

Info

Publication number
JP2024054286A5
JP2024054286A5 JP2024018466A JP2024018466A JP2024054286A5 JP 2024054286 A5 JP2024054286 A5 JP 2024054286A5 JP 2024018466 A JP2024018466 A JP 2024018466A JP 2024018466 A JP2024018466 A JP 2024018466A JP 2024054286 A5 JP2024054286 A5 JP 2024054286A5
Authority
JP
Japan
Prior art keywords
seq
cdr1
cdr2
cdr3
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024018466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024054286A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/022272 external-priority patent/WO2019178356A1/en
Application filed filed Critical
Publication of JP2024054286A publication Critical patent/JP2024054286A/ja
Publication of JP2024054286A5 publication Critical patent/JP2024054286A5/ja
Priority to JP2026076105A priority Critical patent/JP2026119147A/ja
Pending legal-status Critical Current

Links

JP2024018466A 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法 Pending JP2024054286A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026076105A JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862643040P 2018-03-14 2018-03-14
US62/643,040 2018-03-14
US201862657151P 2018-04-13 2018-04-13
US62/657,151 2018-04-13
PCT/US2019/022272 WO2019178356A1 (en) 2018-03-14 2019-03-14 Engineered cells, t cell immune modulating antibodies and methods for using the same
JP2020548722A JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020548722A Division JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026076105A Division JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2024054286A JP2024054286A (ja) 2024-04-16
JP2024054286A5 true JP2024054286A5 (cg-RX-API-DMAC7.html) 2024-07-25

Family

ID=67908100

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548722A Withdrawn JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2026076105A Pending JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020548722A Withdrawn JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026076105A Pending JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Country Status (5)

Country Link
US (2) US12258378B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765070A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021518104A (cg-RX-API-DMAC7.html)
AU (2) AU2019235900B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019178356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7649239B2 (ja) 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法
CA3141926A1 (en) 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
CA3159308A1 (en) * 2019-12-02 2021-06-10 Wayne A. Marasco Antibodies against pd-l1 and methods of use thereof
JP7752621B2 (ja) * 2020-02-17 2025-10-10 ミルテニー バイオテック ベー.フェー. ウント コー. カー・ゲー 腫瘍微小環境細胞に対するキメラ抗原受容体(car)を有するパーソナライズされた細胞を提供する方法
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
WO2023147776A1 (en) * 2022-02-07 2023-08-10 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
CN114686592B (zh) * 2022-05-30 2022-09-09 广东忠信生物科技有限公司 一种多类型靶标联合检测的试剂盒及制备方法、使用方法
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009134962A2 (en) * 2008-04-30 2009-11-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
EP3957653A1 (en) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012143524A2 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9598496B2 (en) * 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP4292657A3 (en) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EP3119804A2 (en) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015164865A1 (en) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016033547A1 (en) * 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and oprl
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3029067A1 (en) * 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
RU2017125531A (ru) 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2998589A1 (en) * 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.

Similar Documents

Publication Publication Date Title
JP2021518104A5 (cg-RX-API-DMAC7.html)
JP2022512684A5 (cg-RX-API-DMAC7.html)
KR20230147617A (ko) 아데노신 수용체에 관한 방법 및 조성물
EP3541841B1 (en) Anti-pd-1 antibodies and compositions
US10544217B2 (en) Anti-PD-1 antibodies
JP2022512653A5 (cg-RX-API-DMAC7.html)
US7563869B2 (en) Substance specific to human PD-1
ES2643887T3 (es) Combinación de anticuerpos anti-KIR y anticuerpos anti-PD-1 para tratar el cáncer
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
CN111183159B (zh) 靶向cd137的抗体及其使用方法
EP3470428A1 (en) Antibodies targeting cd137 and methods of use thereof
JP2022504802A5 (cg-RX-API-DMAC7.html)
EP1242823B1 (en) Selecting library members capable of binding to epitopes
BR122017025062B1 (pt) anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN115850476B (zh) 一种cll1抗体及其应用
JP2010031015A (ja) インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体
TW201945541A (zh) 具抗原專一性的t細胞及其用途
Gjetting et al. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
CN112262156A (zh) 抗her2抗体
TW202216768A (zh) Lair-1結合劑及其使用方法
JP2022544825A5 (cg-RX-API-DMAC7.html)
CN114206919A (zh) 靶向taci的抗体和嵌合抗原受体
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2024506550A5 (cg-RX-API-DMAC7.html)
EP3956362A1 (en) Bioassay for t-cell co-stimulatory proteins containing fc domains